Navigation Links
MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
Date:1/7/2008

edical director/head of clinical development, rounds out the MedImmune Ventures team as senior vice president.

About MedImmune Ventures

MedImmune Ventures is a corporate venture capital fund with $300 million under management that invests in early-to late-stage, public or private biopharmaceutical companies focused on discovering and developing human therapeutics. The primary strategic areas of interest are antibodies and peptides/proteins, other various biologics, small molecules and vaccines. MedImmune Ventures will also examine investment opportunities related to new technologies and programs related to translational sciences, and the intersection between diagnostics and drug development. Investments range from seed funding through public investments in private equity.

Created to promote entrepreneurship and to give MedImmune early access to the newest companies and discoveries, MedImmune Ventures leverages a broad base of internal resources with expertise ranging from R&D to marketing of biologics and small molecules, which closely guide its investment strategies. The fund has provided MedImmune with early exposure to new technologies and therapeutic approaches and the opportunity to establish relationships that have eventually led to R&D collaborations and acquisitions. Now as a part of AstraZeneca, the fund will seek to continue implementing its investment plan while broadening its investment interests and leveraging the parent company's internal resources as well as its relationships with academic institutions, other biotechnology companies and worldwide venture capital firms.

Parties interested in seeking funding should direct inquiries to medimmuneventures@medimmune.com.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is dedicated to ad
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
3. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
6. MedImmune Announces Seven Key Promotions and New Hires
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
10. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
11. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014  CSSi ( www.CSSiEnroll.com ), the leader ... industry, is pleased to announce its participation in ... October.  President Chris Trizna will be ... Clinical Trials New England conference sponsored by Arena ... annual Site Solutions Summit sponsored by the Society ...
(Date:10/1/2014)... , Cambridge Semantics, the leading provider of Smart ... announced its participation in the 2014 Big Data Leaders ... provide semantic linkage and meaning to Big Data to ... diverse data. Ben Szekely, vice president and founding engineer ... sciences data lake” and an approach for collecting and ...
(Date:10/1/2014)... Weighing applications in pharmaceutical manufacturing ... product. However, while the pharmaceutical industry is one ... Good Manufacturing Practices (GMP) usually provide only broad ... to interpret these guidelines and assess process risks ... TOLEDO experts have created a new white paper, ...
(Date:10/1/2014)... The participants committed to not only creating ... own time adjusting, tweaking and testing virtual models and ... for judging. , “I enjoyed being involved as a ... “The entries showed a commendable range exploring the technical ... print medium and the creativity of the contestants.” , ...
Breaking Biology Technology:Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 3Cambridge Semantics to Present ‘A Useful Approach to Big Data’ at 2014 Big Data Leaders Forum 2Comply with Weighing-Related Regulations in Pharma Manufacturing 2Array Architects Challenges Staff to Create with 3D Printer 2
... ANTONY, France, July 10 , - 1st Half-Year Sales Up 16%, - Revision Upwards of 2008 Sales Growth Guidance: (greater than or equal,to)12%, EUR millions ... 07/06 2008 08/07 ... ... Europe (1) 20.5 72 23.2 72 13 26.8 71 ...
... July 10 Today,s Pharmaceutical Research,and ... to end the practice,of providing non-educational ... toward,enhancing the value of the physician/industry ... CMR Institute, a leading non-profit,organization dedicated ...
... July 10 Quest Diagnostics,Incorporated (NYSE: DGX ), ... announced today that its second-quarter,2008 results will be made ... that it will hold its quarterly conference call with ... on that day., The public may access the ...
Cached Biology Technology:Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth 2CMR Institute: Education Key to Physician/Representative Relationship 2Quest Diagnostics to Release Second Quarter 2008 Financial Results 2
(Date:9/30/2014)... some hope: A new research report published in October ... , explains how scientists developed a synthetic version of ... development in human and mouse eggs similar to the ... during fertilization. , "We believe that the results of ... understanding of human fertilization by providing a precise answer ...
(Date:9/30/2014)... suite of perilous threats in today,s ocean. From ... change, fragile coral ecosystems are disappearing at unprecedented ... species of corals surrounding the island of Moorea ... their tropical environment: coral guard-crabs. New research from ... Station scientist Seabird McKeon and the museum,s predoctoral ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may ... week in mBio , the online open-access journal of ... from the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal ... ramosum gained weight when fed a high-fat diet. Mice ... obese even when consuming a high-fat diet, and mice that ...
Breaking Biology News(10 mins):Synthetic sperm protein raises the chance for successful in vitro fertilization 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2
... food safety and traceability will be showcased at a ... The Food Integrity and Traceability Conference will take place ... leading scientists, food standards regulators and agri-food producers from ... Institute for Global Food Security and from across the ...
... BRCA2 gene have a worse prognosis and lower survival rates ... This is the main conclusion to come out of a ... Oncology , in which David Olmos, Head of the Prostate ... National Cancer Research Centre (CNIO), has taken part in, along ...
... making the disease difficult to study. However, K9 bone ... the disease, and over 10,000 canine patients develop the ... Cancer Center and the Colorado State University Flint Animal ... used easily available K9 osteosarcoma samples to discover a ...
Cached Biology News:International conference will put agri-food supply chain under the microscope 2First genetic factor in prostate cancer prognosis identified 2AACR news: K9 osteosarcoma samples identify drivers of metastasis in pediatric bone cancer 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... Cyclin D2 is a G1 cyclin ... strong candidate for a proto-oncogene. cyclin ... cdk4 and/or cdk6. Species Reactivity: Human, ... NeoMarkers DCS-3.1 MAb is particularly well suited ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: